Regulatory Updates on Biosimilars


Competitions and/or success in the present pharma industry are determined by the winning patent strategy which mostly pertains to the generic market entry. Generic and branded drug manufacturers both the patent strategy proximally belongs to the Hatch-Waxman Act statutory scheme and ANDA litigations. The Hatch-Waxman Act enacted in 1984 with amendment in 2003 facilitated the entry of generics at an early stage-thereby finishing the battle of branded generic ANDA of blockbuster drugs. All the same the Biologics Price Competition and Innovation (BPCI) Act has maximized the branded-generic patent duel in the biologics realm by imposing a litigated framework on follow-on-biologics.



An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6% with one generic competitor, but jumps to 48% with two generic competitors, 56% with three, 61% with four and 67% with five generic producers in a market. Within 2 years of the expiration of the patent of the popular drug Zantac in 1997, generics of Zantac accounted 90% of the treatment’s total sales, and the price for patients was about 10% of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners successfully received EMEA approval for the first European biogenerics, two products containing human growth hormone.


  • Licensing of biosimilars
  • BLA filing for biosimilars
  • Regulatory prospects of BRIC countries
  • Biowaiver approval for biosimilars

Related Conference of Regulatory Updates on Biosimilars

June 21-22, 2021

1 st Global Summit on Generic Drugs and Quality Control

Prague, Czech Republic
June 24-24, 2021

1 st Pharmaceutical and Pharma Industry

London, UK
June 25-25, 2021

4thPharmaceutical Research and Drug Discovery

Singapore City, Singapore
June 25-25, 2021

Pharma 2021

London, UK
June 26-26, 2021

3D Priniting

Chicago, Aland Islands
July 06-07, 2021

14th Global Pharmacovigilance And Clinical Trials Summit

Albufeira, Portugal
July 10-11, 2021

2 nd Pharma Expo China

Tokyo, Japan
July 13-14, 2021

24th Asia Pacific Pharma Congress

Melbourne,
July 26-27, 2021

36th World Pharmacology and Therapeutics Forum

Paris, France
July 30-30, 2021

12th World Congress on Bioavailability and Bioequivalence

Prague, Czech Republic
August 16-17, 2021

Global summit on Cosmetic & Reconstructive Surgery

Tokyo, Japan
August 16-17, 2021

34rd World Congress on Pharmacology

London, UK
August 23-24, 2021

7th World Congress on Medicinal Plants and Marine Drugs

Prague, Czech Republic
August 25-25, 2021

7th International Conference on Surgeons

London, UK
August 30-31, 2021

20th Medicinal & PharmaceuticalSciences Congress

London, UK
September 13-14, 2021

3rd World Congress on Drug Discovery and Drug Design

Tokyo, Japan
September 17-18, 2021

9th International Conference on Clinical Trials

Montreal, Canada
September 20-21, 2021

Asia Pacific Pharmaceutics & Drug Delivery Congress

Tokyo, Japan
September 27-28, 2021

2 nd World Pharma Expo

Tokyo, Japan
October 05-06, 2021

International Congress on Drug Delivery

Auckland, Newzealand
October 21-22, 2021

2nd Annual Congress on Antibiotics and Bacterial Infections

Geneva, Switzerland
October 29-30, 2021

12th Annual Biomarkers and Clinical Research Congress

Vancouver, Canada
November 01-02, 2021

15th World Drug Delivery Summit

Rome, Italy
November 16-17, 2021

World Congress on Biologics and Biosimilars

Osaka, Japan
November 26-27, 2021

World Biosimilars & Biologics Congress

Vancouver, Canada
December 02-03, 2021

17th Annual Congress on Pharmacology and Toxicology

Tokyo, Japan
December 02-03, 2021

International Conference on Bio Pharmaceutics

Auckland, Newzealand
December 07-08, 2021

2nd International Conference on Biotechnology and Healthcare

Auckland, Newzealand
December 15-16, 2021

12th World Congress on Bioavailability and Bioequivalence

Bali, Indonesia

Regulatory Updates on Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in